The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.
Sosei Heptares and PharmEnable will harness artificial intelligence-enabled technology and advanced chemistry to explore neurological disease solutions.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
The CRO is working with PWNHealth and Fulgent Genetics to enhance its monitoring program, including the addition of at-home COVID-19 testing capabilities.
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
As healthcare providers and other high-priority patients begin receiving the vaccines, the agency continues to act to help the national pandemic response.
Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.
The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.
The GoGetTested response operating system, to date used to administer more than 200,000 tests, now will scale to include health systems in more states.
A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.
The Medical Data Platform, an RPM solution from VivaLNK, handles clinical trials, cardiac monitoring, remote and in-patient monitoring and other tasks.